The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.

Published in: European journal of clinical pharmacology (2024)

Concomitant use of betablockers with sunitinib or pazopanib is associated with longer overall survial and progression free survival.

Keyphrases